TW202332691A - Ige調節的疾病的治療 - Google Patents

Ige調節的疾病的治療 Download PDF

Info

Publication number
TW202332691A
TW202332691A TW111138537A TW111138537A TW202332691A TW 202332691 A TW202332691 A TW 202332691A TW 111138537 A TW111138537 A TW 111138537A TW 111138537 A TW111138537 A TW 111138537A TW 202332691 A TW202332691 A TW 202332691A
Authority
TW
Taiwan
Prior art keywords
ige
antibody
seq
amino acid
acid sequence
Prior art date
Application number
TW111138537A
Other languages
English (en)
Chinese (zh)
Inventor
郭必盛
李昭鋐
李元鳳
林淑菁
長怡 王
Original Assignee
聯合生物製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 聯合生物製藥股份有限公司 filed Critical 聯合生物製藥股份有限公司
Publication of TW202332691A publication Critical patent/TW202332691A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW111138537A 2021-10-12 2022-10-12 Ige調節的疾病的治療 TW202332691A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163254729P 2021-10-12 2021-10-12
US63/254,729 2021-10-12

Publications (1)

Publication Number Publication Date
TW202332691A true TW202332691A (zh) 2023-08-16

Family

ID=85981469

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111138537A TW202332691A (zh) 2021-10-12 2022-10-12 Ige調節的疾病的治療

Country Status (7)

Country Link
US (1) US20230122862A1 (https=)
EP (1) EP4416176A4 (https=)
JP (1) JP2024538791A (https=)
KR (1) KR20240082392A (https=)
CN (1) CN118119641A (https=)
TW (1) TW202332691A (https=)
WO (1) WO2023061390A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024050455A2 (en) * 2022-08-31 2024-03-07 Heitmeyer Jamie Nicole Anti-rhd antibodies for treating inflammatory dermal condition
WO2025015286A2 (en) * 2023-07-13 2025-01-16 Inhibrx Biosciences, Inc. Ige binding proteins and uses thereof
KR20260042217A (ko) 2023-07-13 2026-03-30 인히브릭스 바이오사이언스, 인크. IgE 결합 단백질 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012204078A1 (en) * 2007-02-15 2012-08-02 Astrazeneca Ab Binding members for IgE molecules
KR20140119777A (ko) * 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
DK3157951T3 (da) * 2014-06-17 2020-08-17 Academia Sinica Humaniserede anti-ige-antistoffer, der tværbinder cd23 på b-lymfocytter, men ikke sensibiliserer mastceller
JP6068582B2 (ja) * 2015-08-07 2017-01-25 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｂリンパ球上のヒトｍＩｇＥに結合可能な抗ＣεｍＸ抗体
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
WO2019085902A1 (en) * 2017-10-31 2019-05-09 Fountain Biopharma Inc. Treating ige-mediated allergic diseases

Also Published As

Publication number Publication date
JP2024538791A (ja) 2024-10-23
WO2023061390A1 (en) 2023-04-20
EP4416176A1 (en) 2024-08-21
KR20240082392A (ko) 2024-06-10
EP4416176A4 (en) 2025-12-31
CN118119641A (zh) 2024-05-31
US20230122862A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
US20240209102A1 (en) Methods of treating inflammatory conditions
US20250059270A1 (en) Il-6 antibodies
EP3489258A1 (en) Il-6 antagonists and uses thereof
JP2021514664A (ja) 抗クローディン１８．２抗体及びその使用
CN110662768B (zh) 治疗性抗cd40配体抗体
TW202332691A (zh) Ige調節的疾病的治療
JP2020536495A (ja) 抗ｌａｇ−３抗体及びその使用
EP4454659A2 (en) Anti-par-2 antibodies and methods of use thereof
WO2022179516A1 (zh) 抗TrkA抗体或其抗原结合片段、其制备方法和应用
WO2013103783A1 (en) Murine il-13 antibodies
HK40027816A (en) Improved il-6 antibodies
HK40102410A (en) Improved il-6 antibodies
HK40115557A (en) Anti-par-2 antibodies and methods of use thereof
WO2024187149A2 (en) Dual inhibitor kallikrein antibodies and uses thereof
HK40111253A (zh) 抗pacap抗体的组合物和方法
HK40015379B (zh) 治疗性抗cd40配体抗体
HK1244008B (en) Improved il-6 antibodies